Allogeneic stem cell transplantation (alloSCT) is an essential treatment option for the various hematopoietic neoplasms. Its efficacy in maintaining long-lasting remissions and cure is mainly based on the graft-versus-leukemia (GvL) effect, which is mediated by the donor immune cells 1, 2 and can be enhanced by donor lymphocyte infusions (DLI).
3,4 AML with myelodysplasia-related changes or therapy-related AML (tAML), two distinct subgroups in the current World Health Organization classification of myeloid neoplasms and leukemias frequently termed non-de novo AML in daily clinical routine, are commonly associated with inferior outcome. This is due to the presence of an unfavorable genetic risk profile, poor response to induction chemotherapy, advanced age and the presence of comorbidities. 5 We retrospectively analyzed 204 patients with non-de novo AML or advanced myelodysplastic syndrome with excess of blasts-2 transplanted at our center between September 1995 and June 2015 (Table 1) . Conditioning, GvHD prophylaxis and supportive care were carried out as described previously. 6 Acute GvHD (aGvHD) and chronic GvHD (cGvHD) were graded according to standard criteria. 7 Patients with aGvHD I received topical treatment only. Therapy of aGvHD II-IV consisted of prednisolone 2 mg/kg for 7 days, which was gradually tapered thereafter. 8 DLI were derived either from the granulocyte-CSF-stimulated PBSC graft or collected separately without growth factor stimulation and aliquoted and cryopreserved by CD3+ cells count as follows: 1 × 10 6 ; 5 × 10 6 ; 10 × 10 6 ; and 50 × 10 6 /kg recipient body weight. In patients transplanted from a matched unrelated donor, the starting dose was 1 × 10 6 /kg CD3+ cells; in matched related donor recipients, first DLI contained 5 × 10 6 /kg CD3+ cells. Indication for DLI was prophylactic in patients treated with Flamsa-reduced intensity conditioning, pre-emptive in patients with a persistent/ recurrent molecular marker or progressive mixed chimerism with 45% recipient cells in the bone marrow in the absence of hematologic relapse, or hematologic relapse. DLI were paused in case GvHD occurred or when molecular remission or 100% donor chimerism was achieved. DLI were given at 4-week intervals.
Remission status and chimerism were tested by bone marrow analysis in 3-month intervals. Statistical analyses were performed using NCSS 10 (NCSS; Kaysville, UT, USA) and SPSS 22 (SPSS; Chicago, IL, USA). Overall survival (OS) and disease-free survival (DFS) were determined by the Kaplan-Meier method. Relapse and non-relapse mortality (NRM) were calculated as cumulative incidences (CI-R and CI-NRM) with death from any cause and relapse as competing events. Statistical significance was tested univariately by log-rank test for OS and DFS, or Gray's test for CI-R and CI-NRM (P o0.05, two-sided). For cGvHD and DLI Landmark analyses were performed. To this end, all patients with an event or censored before the corresponding landmark (GvHD: 3.0 months; DLI: 2.1 months) were excluded from the analysis. For univariate and multivariate analyses the Cox proportional hazard regression model was used. At first, a univariate model was calculated for age, disease subtype and status, cytogenetic risk group, Karnofsky performance status (KPS), comorbidities (hematopoietic cell transplantation-specific comorbidity index; HCT-CI), treatment before alloSCT, conditioning, donor type, aGvHD, cGvHD and DLI. Thereafter, variables showing statistical significance at a level of Po 0.1 were entered into multivariate analyses (forward logistic regression, inclusion P = 0.05, exclusion P = 0.10; stepwise entry). Hazard ratios (HRs) are given with a 95% confidence interval (CI) and corresponding P-values. cGvHD und DLI were entered into the multivariate model as time-dependent covariates.
Median follow-up was 14.5 (range: 0.1-243.7) months for all patients and 46.3 (range: 6.0-243.7) months for surviving patients. At 1, 3, 5 and 10 years after alloSCT, OS (95% CI) or DFS (95% CI) was 56% (49-63%), 40% (38-47%), 38% (31-45%) and 29% (20-38%), or 50% (43-57%), 38% (31-45%), 36% (29-43%) and 27% (19-35%), respectively. At the same time points the CI-R (95% CI) or the CI-NRM (95% CI) was 30% (24-37%), 36% (30-43%), 37% In univariate analyses (Supplementary Table 1) , age above the median was associated with an inferior OS, whereas AML with myelodysplasia-related changes, remission status, unfavorable cytogenetics, KPS o 90%, HCT ⩾ 1 and non-myeloablative conditioning (non-MAC) were associated with an inferior OS and DFS, respectively. AML with myelodysplasia-related changes, remission status, unfavorable cytogenetics, comorbidities and non-MAC were associated with a higher CI-R. KPS o90% and HCT ⩾ 1 were associated with an increased CI-NRM. In patients with aGvHD (any grade) or cGvHD (any grade) OS and DFS were significantly higher. Whereas aGvHD or cGvHD did not affect NRM, relapse incidence was significantly lower as compared to patients without GvHD. When entered into multivariate analysis (Supplementary Table 2 ), OS was independently predicted by age, KPS and HCT-CI. KPS and comorbidities independently predicted DFS. Relapse was independently predicted by comorbidities. KPS and comorbidities were independent predictors for NRM. Furthermore, multivariate analysis revealed that cGvHD is an independent predictor for OS (HR 0.53 (95% CI: 0.33-0.86), P = 0.011), DFS (HR 0.56 (95% CI: 0.33-0.94), P = 0.027) and CI-R (HR 0.26 (95% CI: 0.11-0.62), P = 0.002). As shown in Figure 1a , the median OS or DFS in patients with cGvHD was significantly higher as compared to patients without cGvHD, that is, 119.8 versus 17.8 months (P o 0.001) or 94.4 versus 15.1 months (P = 0.003). This was paralleled by a significantly lower CI-R in patients with cGvHD, that is, 20.2% versus 45.4% in patients without cGvHD at 5 years after alloSCT (P o0.001).
Altogether 41/204 patients (20.0%) received DLI given either prophylactically (3/41 patients, 7.3%), pre-emptively (24/41 patients, 58.5%) or at hematologic relapse (14/41 patients, 34.1%). Median interval between alloSCT and first DLI was 33 (range: 4-208) weeks. The median total CD3+ cell dose given was 6 × 10 6 /kg (range: 1.0 × 10 6 -10 × 10 6 /kg). Following DLI, 19/41 patients (46.3%) developed aGvHD, whereas cGvHD occurred in 17/41 patients (41.2%). In patients given prophylactic/pre-emptive DLI OS and DFS were significantly higher (OS: P = 0.005, DFS: Po 0.001). This was paralleled by a significantly lower CI-R (P o 0.001) (Figure 1b) . Although there might be a tendency toward a better outcome, statistical significance in terms of OS (HR 0.67 (95% CI: 0.40-1.10), P = 0.118), DFS (HR 0.64 (95% CI: 0.36-1.14), P = 0.130), CI-R (HR 0.49 (0.24-1.01), P = 0.053) or CI-NRM (HR 0.96 (95% CI: 0.36-2.54), P = 0.927) was missed in multivariate analyses. Abbreviations: alloSCT = allogeneic stem cell transplantation; ATG = anti-thymocyte globulin; CHR = complete hematologic remission; BM = bone marrow; EB = excess of blasts; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; KPS = Karnofsky performance status; MAC = myeloablative conditioning; MDS = myelodysplastic syndrome; mMUD = mismatched unrelated donor; MRD = matched related donor; MUD = matched unrelated donor; RIC = reduced intensity conditioning; SWOG/ECOG = Southwest Oncology Group/Eastern Cooperative Oncology Group. Cytogenetic risk was categorized according to the SWOG/ECOG. Comorbidities were assessed using the HCT-CI. For cGvHD a landmark of 3 months was chosen (corresponding to the first occurrence of cGvHD), whereas for DLI the landmark was set to 2.1 months (corresponding to the first administration of DLI).
In our analysis cGvHD is among the strongest negative predictors for leukemic relapse, which was paralleled by a substantial survival benefit for OS and DFS, respectively. Remarkably, we did not observe a significant negative impact of cGvHD on NRM. The same is true for aGvHD. Notably, severe cGvHD was observed in only 18/204 patients (8.8%). Likewise, aGvHD°III/IV was rather rare and affected only 13.7% of the patients in our series, which may explain this unexpected finding. Because of the small number of patients in each aGvHD or cGvHD subgroup, we could not perform separate analyses. Nevertheless, our data underline that cGvHD is a surrogate for alloreactivity, which should be the basis for the beneficial GvL effect. 1, 9, 10 In contrast to DLI given at hematologic relapse, pre-emptive or prophylactic were highly effective and resulted in a significant survival benefit. 11, 12 Notably, multivariate analyses failed to identify DLI as an independent predictor for outcome, that is, for survival or relapse rate.
AlloSCT allowed one-third of patients to survive disease-free for 5 years and longer, which is in line with previous reports.
9,13-15 Notably, relapses beyond 5 years were rare and affected only 4/204 patients (2%), which underscores that alloSCT is highly curative. Still, relapse incidence was as high as 30% at 1 year post transplant. This most likely reflects the inherent resistance of the malignant cells toward direct cytotoxic effects of chemotherapy and illustrates that immune-mediated killing to eradicate the malignant cell clone(s) needs time. 1, 9 Post-transplant maintenance therapy could help to improve the results in selected patient subgroups. Specific considerations, for example, when to initiate treatment (prophylactic versus pre-emptive), who to treat (all versus high-risk patients) or when to consider intensive chemotherapy rather than hypomethylating agents, need further investigation. NRM, albeit steeply increasing within the first 2 years after alloSCT, does not reach a solid plateau before 10 years after alloSCT. This may be due to advanced patient age in our cohort, which is an independent predictor for OS. Notably, none of the patients with therapy-related disease had a relapse of the antecedent solid tumor.
Despite the limitations of a retrospective single-center analysis, our data underline the potential of alloSCT to cure patients with high-risk myeloid malignancies. Especially, cGvHD and adoptive immunotherapy by DLI augment antitumor activity and play a central role in maintaining long-term remissions and cure.
